Transthyretin is highly expressed in MS patient serum [93], suggesting that there may be a failure in transthyretin transfer from the blood to the CSF and the brain and that pharmacological enhancement of that pathway may increase thyroxin availability in the brain and spinal cord and promote remyelination in MS patients. Here, TTR is linked to myeloid sarcoma.